FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

830160007: Crizanlizumab (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2020. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
3880787013 Crizanlizumab (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
3880788015 Crizanlizumab en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Crizanlizumab (substance) This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Selective adhesion molecule inhibitor true Inferred relationship Some
Crizanlizumab (substance) Is a Selective adhesion molecule inhibitor true Inferred relationship Some
Crizanlizumab (substance) Is a Monoclonal immunoglobulin G (substance) true Inferred relationship Some
Crizanlizumab (substance) This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. A substance that modifies the immune response or the functioning of the immune system. true Inferred relationship Some
Crizanlizumab (substance) Is a anticorps monoclonal chimérique souris-humain d'isotype IgG false Inferred relationship Some
Crizanlizumab (substance) Is a Immunosuppressant (substance) true Inferred relationship Some
Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing only crizanlizumab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Crizanlizumab (substance) Inferred relationship Some 1
Product containing only crizanlizumab in parenteral dose form (medicinal product form) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Crizanlizumab (substance) Inferred relationship Some 1
Crizanlizumab-containing product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Crizanlizumab (substance) Inferred relationship Some 1
Product containing crizanlizumab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Crizanlizumab (substance) Inferred relationship Some 1

This concept is not in any reference sets

Back to Start